Numerous clinical trials evaluate osimertinib across all development phases, primarily targeting non-small cell lung cancer with EGFR activating mutations—including Exon 19 deletions, L858R, and Exon 20 insertions—alongside limited studies in colorectal cancer. Sponsored by leading pharmaceutical companies and academic institutions, these trials evaluate neoadjuvant, adjuvant, and first-line settings across various recruitment statuses, including recruiting and active non-recruiting. Additionally, several clinical trials investigate novel combination strategies and pharmacokinetic enhancements to overcome resistance mechanisms and optimize therapeutic outcomes.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07642024 | RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-07-24 | PHASE2; PHASE3 |
| NCT07680790 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2026-09-30 | PHASE3 |
| NCT07005102 | RECRUITING | Non-Squamous Non-Small Cell Lung Cancer |
AbbVie |
2025-08-03 | PHASE2; PHASE3 |
| NCT05624996 | RECRUITING | Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8 |
NRG Oncology |
2023-07-12 | PHASE3 |
| NCT06053099 | RECRUITING | Non Small Cell Lung Cancer; EGFR Activating Mutation; EGFR DEL19; EGFR L858R |
Intergroupe Francophone de Cancerologie Thoracique |
2024-01-22 | |
| NCT07738172 | RECRUITING | Lung Neoplasms, Non-Small Cell Lung Cancer |
National Taiwan University Hospital |
2026-08-01 | PHASE3 |
| NCT06618287 | RECRUITING | Lung Cancer; Breast Cancer |
Bristol-Myers Squibb |
2025-02-04 | PHASE1; PHASE2 |
| NCT07640789 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer Stage III |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-06 | PHASE3 |
| NCT07155187 | RECRUITING | Non-Small Cell Lung Cancer |
AbbVie |
2025-12-10 | PHASE2; PHASE3 |
| NCT07073365 | RECRUITING | Non-Small Cell Lung Cancer; Epidermal Growth Factor Receptor |
Pusan National University Hospital |
2025-07-01 | PHASE2 |
| NCT07279935 | RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2026-05-26 | PHASE4 |
| NCT05142189 | RECRUITING | Non-Small Cell Lung Cancer |
BioNTech SE |
2022-06-17 | PHASE1 |
| NCT07710612 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive |
Abbisko Therapeutics Co, Ltd |
2026-08-31 | PHASE2 |
| NCT07285148 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer; EGFR Mutation; Metastatic Lung Cancer; MET Alteration |
Beijing Pearl Biotechnology Limited Liability Company |
2026-06 | PHASE1; PHASE2 |
| NCT05526755 | ACTIVE_NOT_RECRUITING | Stage II-IIIB Non-small Cell Lung Carcinoma |
AstraZeneca |
2023-03-06 | PHASE2 |
| NCT04665206 | RECRUITING | Solid Tumor, Adult; Mesothelioma; NSCLC |
Vivace Therapeutics, Inc |
2021-03-24 | PHASE1; PHASE2 |
| NCT05546866 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2023-02-09 | PHASE2 |
| NCT06436144 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer; EGFR Gene Mutation; Non Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2024-06 | PHASE2 |
| NCT07295821 | RECRUITING | Lung Cancer |
AstraZeneca |
2026-04-01 | PHASE2 |
| NCT07153055 | RECRUITING | Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer |
Misty Shields |
2026-08 | PHASE1; PHASE2 |
| NCT07379476 | RECRUITING | Lung Cancer (NSCLC) |
Chinese University of Hong Kong |
2026-02-11 | PHASE2 |
| NCT06970639 | RECRUITING | NSCLC Patients With Brain Metastasis |
Allist Pharmaceuticals, Inc. |
2024-09-26 | PHASE3 |
| NCT07185997 | RECRUITING | Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer; EGFR P-Loop and Alpha C-Helix Compressing; EGFR PACC; EGFR Uncommon Mutations |
ArriVent BioPharma, Inc. |
2025-12-17 | PHASE3 |
| NCT07058519 | RECRUITING | Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) |
Shanghai Chest Hospital |
2025-09-23 | PHASE2 |
| NCT06709274 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2024-11 | |
| NCT06206850 | RECRUITING | Non-squamous NSCLC |
Jair Bar, M.D., Ph.D. |
2024-02-19 | PHASE2 |
| NCT07622186 | RECRUITING | Non-Small Cell Lung Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2026-07-15 | PHASE2 |
| NCT06908772 | NOT_YET_RECRUITING | Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression |
Shanghai JMT-Bio Inc. |
2025-04-01 | PHASE2; PHASE3 |
| NCT06895928 | RECRUITING | Advanced Solid Tumors |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2025-03-28 | PHASE2 |
| NCT06838273 | RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-02-24 | PHASE3 |
| NCT03833154 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
AstraZeneca |
2019-03-06 | PHASE3 |
| NCT07486648 | NOT_YET_RECRUITING | Lung Cancer (NSCLC); Lung Cancer (Non-Small Cell); Advanced Non-small-cell Lung Cancer |
Shanxi Province Cancer Hospital |
2026-05-15 | PHASE1; PHASE2 |
| NCT07206498 | RECRUITING | Non Small Cell Lung Cancer (NSCLC) |
Wayshine Biopharm, Inc. |
2025-10-17 | PHASE1; PHASE2 |
| NCT07177092 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer; EGFR |
Jianxing He |
2025-09-08 | PHASE2 |
| NCT06486142 | RECRUITING | Non-Small Cell Lung Cancer |
Region Skane |
2022-09-21 | PHASE3 |
| NCT05647122 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms |
AstraZeneca |
2022-12-21 | PHASE1 |
| NCT07375316 | RECRUITING | Non Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2025-12-15 | PHASE2 |
| NCT05017025 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2022-02-17 | PHASE1; PHASE2 |
| NCT07079475 | RECRUITING | Non-Small Cell Lung Cancer |
Dizal Pharmaceuticals |
2025-07-30 | PHASE1; PHASE2 |
| NCT05009836 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Hutchison Medipharma Limited |
2021-09-06 | PHASE3 |
| NCT07361705 | RECRUITING | Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment |
Alpha Biopharma (Jiangsu) Co., Ltd. |
2026-01-31 | PHASE1 |
| NCT06093503 | WITHDRAWN | Non-Small Cell Lung Cancer |
AbbVie |
2024-05-31 | PHASE3 |
| NCT07535437 | RECRUITING | Non-Small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2026-04-09 | PHASE1; PHASE2 |
| NCT06350097 | RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2024-04-29 | PHASE3 |
| NCT04486833 | RECRUITING | Carcinoma, Non-Small Cell Lung |
Genprex, Inc. |
2021-09-03 | PHASE1; PHASE2 |
| NCT06824792 | NOT_YET_RECRUITING | Advanced Solid Tumors |
NING LI |
2025-03-01 | PHASE4 |
| NCT03586453 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Dana-Farber Cancer Institute |
2018-08-13 | PHASE2 |
| NCT06829459 | RECRUITING | Non-Small Cell Lung Cancer |
Shanghai JMT-Bio Inc. |
2025-04-03 | PHASE3 |
| NCT07505173 | RECRUITING | Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases |
Tianjin Medical University Cancer Institute and Hospital |
2026-01-01 | PHASE2 |
| NCT05401110 | RECRUITING | Non Small Cell Lung Cancer; Lung Cancer |
Karen Reckamp, MD, MS |
2023-09-15 | PHASE1 |
| NCT06918782 | NOT_YET_RECRUITING | Lung Cancer (NSCLC) |
The University of Hong Kong |
2025-05-01 | PHASE2 |
| NCT06692491 | NOT_YET_RECRUITING | Rare Tumour |
Peking University Shenzhen Hospital |
2025-01-01 | PHASE2 |
| NCT05785741 | RECRUITING | Advanced Solid Tumor |
DualityBio Inc. |
2023-08-17 | PHASE1; PHASE2 |
| NCT07603791 | NOT_YET_RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Shanghai Allink Biotherapeutics Co., Ltd. |
2026-06-30 | PHASE2 |
| NCT06452433 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-06-01 | PHASE2 |
| NCT06741085 | RECRUITING | Non Small Cell Lung Cancer Metastatic |
Memorial Sloan Kettering Cancer Center |
2024-12-13 | PHASE2 |
| NCT07038460 | NOT_YET_RECRUITING | Resectable Non-small Cell Lung Cancer |
Wen-zhao ZHONG |
2025-07 | PHASE2 |
| NCT06142617 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor; EGFR Exon 21 Mutation |
Peking Union Medical College Hospital |
2023-12-01 | PHASE2 |
| NCT05166616 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma |
City of Hope Medical Center |
2022-03-07 | PHASE1 |
| NCT05801029 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer (NSCLC) |
AstraZeneca |
2023-07-18 | PHASE2 |
| NCT03667820 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer (NSCLC) |
University of Texas Southwestern Medical Center |
2018-09-26 | PHASE2 |
| NCT06868485 | RECRUITING | Non Small Cell Lung Cancer |
Wayshine Biopharm, Inc. |
2025-08-18 | PHASE2 |
| NCT05528458 | RECRUITING | Lung Adenocarcinoma |
Samsung Medical Center |
2022-09-11 | PHASE2 |
| NCT04591002 | RECRUITING | Lung Cancer |
Samsung Medical Center |
2022-09-11 | PHASE2 |
| NCT07329322 | RECRUITING | Non-Small Cell Lung Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2026-03-30 | PHASE2 |
| NCT07669779 | RECRUITING | Advanced Non Small Cell Lung Cancer (NSCLC) |
Akeso |
2026-07-10 | PHASE2 |
| NCT05120349 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2022-02-21 | PHASE3 |
| NCT03040973 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors Which Are cMET-dependent |
Novartis Pharmaceuticals |
2017-08-23 | PHASE2 |
| NCT05693090 | WITHDRAWN | NSCLC |
Kura Oncology, Inc. |
2023-02-01 | PHASE1 |
| NCT05880706 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2023-07-19 | PHASE2 |
| NCT07612137 | NOT_YET_RECRUITING | Solid Tumor |
Innovent Biologics (Suzhou) Co. Ltd. |
2026-06-01 | PHASE1; PHASE2 |
| NCT02496663 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2016-05-11 | PHASE1 |
| NCT05642572 | RECRUITING | Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
SWOG Cancer Research Network |
2023-05-05 | PHASE2 |
| NCT03191149 | RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2018-04-25 | PHASE2 |
| NCT03392246 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Dana-Farber Cancer Institute |
2018-01-31 | PHASE2 |
| NCT06557096 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer; Circulating Tumor Cell; EGF-R Positive Non-Small Cell Lung Cancer |
Second Affiliated Hospital of Nanchang University |
2024-08-20 | EARLY_PHASE1 |
| NCT07485452 | RECRUITING | Non-Small Cell Lung Cancer |
Maastricht University Medical Center |
2026-06 | PHASE2 |
| NCT03567642 | ACTIVE_NOT_RECRUITING | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2018-06-12 | PHASE1 |
| NCT06670196 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2024-11-27 | PHASE3 |
| NCT04410796 | RECRUITING | Metastatic Non-small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2020-05-28 | PHASE2 |
| NCT03410043 | ACTIVE_NOT_RECRUITING | Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2018-01-17 | PHASE2 |
| NCT06380348 | NOT_YET_RECRUITING | Local Advanced or Metastatic NSCLC |
Shanghai JMT-Bio Inc. |
2024-04-26 | PHASE3 |
| NCT06014827 | RECRUITING | Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
City of Hope Medical Center |
2024-10-09 | PHASE2 |
| NCT02503722 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2017-03-23 | PHASE1 |
| NCT05629234 | ACTIVE_NOT_RECRUITING | Cancer |
AstraZeneca |
2023-05-08 | PHASE3 |
| NCT07323641 | RECRUITING | Lung Non-Small Cell Carcinoma |
Jonsson Comprehensive Cancer Center |
2026-02-19 | PHASE2 |
| NCT04743505 | ACTIVE_NOT_RECRUITING | Metastatic Non Small Cell Lung Cancer |
Washington University School of Medicine |
2022-01-18 | PHASE1; PHASE2 |
| NCT06752408 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Peking Union Medical College Hospital |
2024-12-17 | PHASE2 |
| NCT04136535 | RECRUITING | NSCLC Stage IV |
Fudan University |
2021-11-18 | PHASE2 |
| NCT04181060 | RECRUITING | Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2020-12-28 | PHASE3 |
| NCT07322783 | RECRUITING | EGFR Positive Non-small Cell Lung Cancer; MET Amplification |
Qingdao Central Hospital |
2025-01-01 | PHASE2 |
| NCT05805631 | RECRUITING | Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor Receptor; Leptomeningeal Metastasis |
Taipei Veterans General Hospital, Taiwan |
2024-08-01 | PHASE2 |
| NCT06507306 | ACTIVE_NOT_RECRUITING | Solid Tumor, Adult |
Kumquat Biosciences Inc. |
2024-06-03 | PHASE1 |
| NCT04413201 | ACTIVE_NOT_RECRUITING | Non-squamous NSCLC |
Michael Hopp |
2020-09-11 | PHASE4 |
| NCT02465060 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2015-08-17 | PHASE2 |
| NCT04780568 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
Ohio State University Comprehensive Cancer Center |
2022-01-18 | PHASE1 |
| NCT06319950 | NOT_YET_RECRUITING | Lung Cancer, Nonsmall Cell |
Taizhou Hospital |
2024-04-01 | PHASE2 |
| NCT04762199 | RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
Emory University |
2021-02-24 | PHASE1 |
| NCT04322890 | RECRUITING | Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation |
Hunan Province Tumor Hospital |
2020-04-16 | PHASE2 |
| NCT07376382 | NOT_YET_RECRUITING | NSCLC |
CSPC Megalith Biopharmaceutical Co.,Ltd. |
2026-06-01 | PHASE3 |
| NCT04285671 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
Jonsson Comprehensive Cancer Center |
2021-01-29 | PHASE1; PHASE2 |
| NCT03909334 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer |
Xiuning Le |
2019-07-25 | PHASE2 |
| NCT07315113 | RECRUITING | EGFR Mutation Positive Non-small Cell Lung Cancer; EGFR Mutated Non-small Cell Lung Cancer Patients |
Nuvectis Pharma, Inc. |
2025-12-18 | PHASE1 |
| NCT07256509 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer |
CSPC Megalith Biopharmaceutical Co.,Ltd. |
2025-11-30 | PHASE2 |
| NCT05998993 | NOT_YET_RECRUITING | EGF-R Positive Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Exon 21 Mutation; EGFR G719X |
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo |
2023-11 | |
| NCT06574347 | RECRUITING | Non-Small-Cell Lung Cancer |
Avistone Biotechnology Co., Ltd. |
2024-08-07 | PHASE2 |
| NCT07229729 | RECRUITING | Non-small Cell Lung Cancer |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2025-11-24 | PHASE2 |
| NCT03122717 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Dana-Farber Cancer Institute |
2017-05-09 | PHASE1; PHASE2 |
| NCT06417814 | RECRUITING | Metastatic Non-small Cell Lung Cancer |
AstraZeneca |
2024-10-04 | PHASE3 |
| NCT03969823 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic NSCLC |
Seoul National University Hospital |
2019-05-23 | |
| NCT06735391 | RECRUITING | Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previously Untreated Systematically NSCLC |
Shanghai JMT-Bio Inc. |
2024-10-23 | PHASE3 |
| NCT06827145 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Cancer |
National Cancer Center, China |
2024-10-14 | PHASE2 |
| NCT06071013 | RECRUITING | Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation |
China Medical University Hospital |
2024-02-23 | PHASE1; PHASE2 |
| NCT02099058 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors Cancer |
AbbVie |
2014-01-15 | PHASE1 |
| NCT06498986 | RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-07-31 | PHASE2 |
| NCT06194448 | ACTIVE_NOT_RECRUITING | Lung Cancer |
AstraZeneca |
2024-04-21 | PHASE2 |
| NCT05261399 | ACTIVE_NOT_RECRUITING | Carcinoma; Non-Small-Cell Lung |
AstraZeneca |
2022-08-03 | PHASE3 |
| NCT05816252 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Klus Pharma Inc. |
2023-04-19 | PHASE2 |
| NCT06304441 | RECRUITING | Leptomeningeal Metastasis |
Guangzhou Medical University |
2024-04-18 | |
| NCT05748093 | UNKNOWN | Non-small Cell Lung Cancer |
Maastricht University Medical Center |
2024-04-01 | PHASE4 |
| NCT04335292 | RECRUITING | Non-Small Cell Lung Cancer |
Mark Vincent |
2021-01-06 | PHASE2 |
| NCT06530719 | NOT_YET_RECRUITING | Lung Neoplasms; Lung Cancer, Nonsmall Cell |
Jin Ying |
2024-07 | PHASE2 |
| NCT04772235 | UNKNOWN | Nsclc |
Instituto Oncológico Dr Rosell |
2022-02-11 | PHASE1 |
| NCT06323148 | NOT_YET_RECRUITING | Lung Cancer; EGFR Gene Mutation; Minimal Residual Disease |
Fudan University |
2024-04-01 | PHASE3 |
| NCT06630325 | TERMINATED | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2025-06-24 | PHASE2 |
| NCT06018688 | UNKNOWN | Non Small Cell Lung Cancer; EGFR Gene Mutation |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2023-09-15 | PHASE2 |
| NCT04868877 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer |
Merus B.V. |
2021-04-28 | PHASE1; PHASE2 |
| NCT05089916 | ACTIVE_NOT_RECRUITING | NSCLC; EGFR Positive Non-small Cell Lung Cancer; Oligoprogression |
AIO-Studien-gGmbH |
2022-01-20 | PHASE2 |
| NCT04721015 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC) |
AbbVie |
2021-02-23 | PHASE1 |
| NCT04769388 | COMPLETED | Non Small Cell Lung Cancer |
Beijing Cancer Prevention & Treatment Society |
2021-12-28 | PHASE2 |
| NCT06296745 | RECRUITING | Leptomeningeal Metastasis |
Guangzhou Medical University |
2025-09-01 | PHASE2 |
| NCT06306456 | RECRUITING | Non-Small Cell Lung Cancer With EGFR Mutation |
Suzhou Genhouse Bio Co., Ltd. |
2024-03-05 | PHASE1; PHASE2 |
| NCT02917993 | COMPLETED | Lung Cancer |
Incyte Corporation |
2016-12-20 | PHASE1; PHASE2 |
| NCT06363734 | RECRUITING | Non-small Cell Lung Cancer; EGFR Activating Mutation; Cell Cycle Deregulation; EGFR-TKI Resistant Mutation |
Tianjin Medical University Cancer Institute and Hospital |
2024-04-09 | PHASE2 |
| NCT03810807 | COMPLETED | Metastatic Non-small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2019-01-17 | PHASE1 |
| NCT05948813 | RECRUITING | NSCLC; EGFR Activating Mutation; Brain Metastases |
TYK Medicines, Inc |
2023-08-17 | PHASE2 |
| NCT04545710 | ACTIVE_NOT_RECRUITING | Lung Cancer |
University of California, San Diego |
2020-11-21 | PHASE2 |
| NCT05020769 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2022-01-06 | PHASE2; PHASE3 |
| NCT04001777 | ACTIVE_NOT_RECRUITING | EGFR Positive Non-small Cell Lung Cancer |
Ascentage Pharma Group Inc. |
2019-07-04 | PHASE1 |
| NCT04695925 | ACTIVE_NOT_RECRUITING | Non-small Cell Carcinoma; EGFR Gene Mutation |
Li Zhang, MD |
2021-03-29 | PHASE3 |
| NCT05281406 | RECRUITING | NSCLC Stage IIIB; NSCLC Stage IV |
Goethe University |
2021-11-12 | PHASE2 |
| NCT06383728 | RECRUITING | Lung Cancer; Carcinoma, Squamous Cell |
The First Affiliated Hospital of Guangzhou Medical University |
2024-04-01 | PHASE2 |
| NCT05773092 | ACTIVE_NOT_RECRUITING | NSCLC |
National Cancer Centre, Singapore |
2023-08-01 | PHASE2 |
| NCT04085315 | COMPLETED | Lung Cancer Metastatic; EGFR Gene Mutation |
Collin Blakely |
2019-11-12 | PHASE1 |
| NCT05954871 | COMPLETED | Colorectal Cancer; Non-Small Cell Lung Cancer |
Genentech, Inc. |
2024-01-08 | PHASE1 |
| NCT05015608 | COMPLETED | Non-small Cell Lung Cancer |
Hutchison Medipharma Limited |
2021-11-22 | PHASE3 |
| NCT06185400 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab Vedotin |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2024-02-01 | PHASE2 |
| NCT04816838 | UNKNOWN | Non Small Cell Lung Cancer |
Yonsei University |
2021-05-10 | |
| NCT06525246 | COMPLETED | Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Cancer; EGFR Mutation-Related Tumors |
Ono Pharmaceutical Co., Ltd. |
2021-08-06 | PHASE1 |
| NCT03804580 | UNKNOWN | Lung Cancer |
Vestre Viken Hospital Trust |
2018-12-01 | PHASE2 |
| NCT06394674 | RECRUITING | Non-Small Cell Lung Cancer |
Changhai Hospital |
2024-05-01 | PHASE2 |
| NCT03944772 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2019-06-25 | PHASE2 |
| NCT05382728 | RECRUITING | NSCLC; EGFR Activating Mutation |
TYK Medicines, Inc |
2022-06-08 | PHASE3 |
| NCT06362980 | UNKNOWN | NSCLC |
National Cancer Center, China |
2024-05-22 | PHASE1 |
| NCT03769103 | ACTIVE_NOT_RECRUITING | Lung Cancer Non-small Cell Stage IV; Brain Metastases |
British Columbia Cancer Agency |
2019-03-19 | PHASE2 |
| NCT02971501 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2018-06-27 | PHASE2 |
| NCT04676477 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer (NSCLC) |
Daiichi Sankyo |
2021-06-11 | PHASE1 |
| NCT06067776 | NOT_YET_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
Jonathan Riess |
2024-01-01 | PHASE1 |
| NCT03865511 | UNKNOWN | Non-small Cell Lung Cancer |
Nantes University Hospital |
2019-04-09 | PHASE2 |
| NCT05033691 | RECRUITING | NSCLC; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Brain Metastases |
Hadassah Medical Organization |
2021-03-09 | |
| NCT05583409 | UNKNOWN | Stage IV Non-small Cell Lung Cancer |
Li Zhang |
2023-01-01 | |
| NCT04988607 | UNKNOWN | Lung Cancer |
Guangdong Association of Clinical Trials |
2021-08 | PHASE2 |
| NCT04765059 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2021-09-12 | PHASE3 |
| NCT04351555 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2020-12-16 | PHASE3 |
| NCT05686434 | RECRUITING | NSCLC, Stage I |
Tianjin Medical University Cancer Institute and Hospital |
2022-10-14 | PHASE2 |
| NCT04862780 | TERMINATED | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR T790M; EGFR C797S; EGFR L858R; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Protein Kinase Inhibitors; Antineoplastic Agents; Thoracic Neoplasms |
Blueprint Medicines Corporation |
2021-06-29 | PHASE1 |
| NCT05228015 | TERMINATED | Solid Tumors, Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions |
Ikena Oncology |
2022-01-07 | PHASE1 |
| NCT03778229 | ACTIVE_NOT_RECRUITING | Carcinoma |
AstraZeneca |
2019-01-09 | PHASE2 |
| NCT04737382 | UNKNOWN | Non-small-cell Lung Carcinoma |
The Netherlands Cancer Institute |
2019-08-22 | |
| NCT04974879 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Qingdao Central Hospital |
2021-07-01 | PHASE2 |
| NCT05498389 | UNKNOWN | Metastatic Lung Non-Small Cell Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; EGFR Mutation-Related Tumors |
Shanghai EpimAb Biotherapeutics Co., Ltd. |
2023-06 | PHASE1; PHASE2 |
| NCT04770688 | COMPLETED | Non-Small Cell Lung Cancer With EGFR Mutation; Locally Advanced Solid Tumor; Metastatic Cancer; Adenocarcinoma of Lung |
Shanghai Chest Hospital |
2020-11-19 | PHASE1; PHASE2 |
| NCT03831932 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2020-03-16 | PHASE1; PHASE2 |
| NCT04870190 | UNKNOWN | NSCLC |
Shanghai Chest Hospital |
2021-06-01 | PHASE3 |
| NCT05085054 | UNKNOWN | Non Small Cell Lung Cancer |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2022-06-01 | PHASE2 |
| NCT06350097 | Not yet recruiting | Non-small Cell Lung Cancer |
AstraZeneca|Daiichi Sankyo |
2024-05-16 | Phase 3 |
| NCT03497767 | COMPLETED | Metastatic Non Small Cell Lung Cancer |
Trans Tasman Radiation Oncology Group |
2019-08-15 | PHASE2 |
| NCT05219162 | COMPLETED | Advanced NSCLC |
AstraZeneca |
2022-02-25 | PHASE4 |
| NCT05120960 | WITHDRAWN | Brain Tumor |
M.D. Anderson Cancer Center |
2023-02-27 | PHASE1 |
| NCT05298176 | COMPLETED | Non-Small Cell Lung Cancer |
Amsterdam UMC, location VUmc |
2022-01-04 | PHASE2 |
| NCT04829019 | UNKNOWN | Neurocognitive |
Sun Yat-sen University |
2021-04-07 | PHASE2 |
| NCT05284994 | UNKNOWN | Nonsmall-cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-03-11 | PHASE1; PHASE2 |
| NCT05163249 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Guangdong Association of Clinical Trials |
2022-05-31 | PHASE2 |
| NCT06323148 | Not yet recruiting | Lung Cancer|EGFR Gene Mutation|Minimal Residual Disease |
Fudan University |
2024-04-01 | Phase 3 |
| NCT05748093 | Recruiting | Non-small Cell Lung Cancer |
Maastricht University Medical Center |
2024-04-01 | Phase 4 |
| NCT06032936 | TERMINATED | NSCLC |
LianBio LLC |
2023-07-27 | PHASE1 |
| NCT05663866 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Janssen Research & Development, LLC |
2023-05-18 | PHASE2 |
| NCT05785208 | UNKNOWN | Non Small Cell Lung Cancer |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2022-06-28 | PHASE4 |
| NCT05489731 | UNKNOWN | Advanced Non-small Cell Lung Cancer |
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. |
2022-09-21 | PHASE1 |
| NCT03732352 | COMPLETED | EGFR Gene Amplification; EGFR Gene Mutation; Glioblastoma; Recurrent Glioblastoma; Supratentorial Glioblastoma; TP53 Wt Allele |
Jonsson Comprehensive Cancer Center |
2018-11-28 | PHASE2 |
| NCT04141644 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) |
University of Utah |
2020-08-20 | PHASE1 |
| NCT04882345 | UNKNOWN | Lung Cancer; EGFR Gene Mutation |
Shanghai Chest Hospital |
2021-07-15 | PHASE2 |
| NCT03521154 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer (Stage III) |
AstraZeneca |
2018-07-19 | PHASE3 |
| NCT05388669 | ACTIVE_NOT_RECRUITING | Advanced or Metastatic Non-small Cell Lung Cancer |
Janssen Research & Development, LLC |
2022-08-05 | PHASE3 |
| NCT06206850 | Not yet recruiting | Non-squamous NSCLC |
Jair Bar M.D. Ph.D.|Sheba Medical Center |
2024-01 | Phase 2 |
| NCT06053099 | Recruiting | Non Small Cell Lung Cancer|EGFR Activating Mutation|EGFR DEL19|EGFR L858R |
Intergroupe Francophone de Cancerologie Thoracique |
2024-01-22 | Not Applicable |
| NCT05954871 | Recruiting | Colorectal Cancer|Non-Small Cell Lung Cancer |
Genentech Inc. |
2024-01-08 | Phase 1 |
| NCT05104281 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Qingdao Central Hospital |
2021-01-01 | PHASE3 |
| NCT04811001 | UNKNOWN | NSCLC |
Fondazione Ricerca Traslazionale |
2020-06-12 | PHASE2 |
| NCT04720976 | COMPLETED | Solid Tumor; NSCLC |
Allist Pharmaceuticals, Inc. |
2021-03-23 | PHASE1; PHASE2 |
| NCT02664935 | COMPLETED | Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma |
University of Birmingham |
2015-05-13 | PHASE2 |
| NCT04908956 | TERMINATED | NSCLC Stage IV; EGFR Gene Mutation |
ETOP IBCSG Partners Foundation |
2022-08-04 | PHASE2 |
| NCT04563871 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) |
Sehhoon Park |
2020-11-17 | PHASE2 |
| NCT05132777 | UNKNOWN | Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations |
Shanghai JMT-Bio Inc. |
2021-11-20 | PHASE2 |
| NCT03239340 | COMPLETED | EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
AstraZeneca |
2018-05-30 | PHASE2 |
| NCT05011487 | RECRUITING | Non-Small Cell Lung Cancer |
Sun Yat-sen University |
2021-08-13 | PHASE2 |
| NCT05493501 | TERMINATED | NSCLC |
EQRx International, Inc. |
2022-12-14 | PHASE3 |
| NCT04487080 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Janssen Research & Development, LLC |
2020-09-30 | PHASE3 |
| NCT05507606 | UNKNOWN | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08-01 | PHASE2 |
| NCT04479306 | COMPLETED | Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2020-06-18 | PHASE1 |
| NCT04988295 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Janssen Research & Development, LLC |
2021-11-17 | PHASE3 |
| NCT03755102 | COMPLETED | EGFR Gene Mutation; Lung Cancer; Lung Cancer Metastatic |
Memorial Sloan Kettering Cancer Center |
2018-11-21 | EARLY_PHASE1 |
| NCT04184921 | COMPLETED | Lung Cancer Non-small Cell Stage IV |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2019-01-01 | PHASE2 |
| NCT02504346 | UNKNOWN | Lung Cancer; Targeted Therapy |
Oslo University Hospital |
2015-08 | PHASE2 |
| NCT05477615 | UNKNOWN | Non-small Cell Lung Cancer |
Jin Hyoung Kang |
2022-08 | PHASE2 |
| NCT06391944 | ACTIVE_NOT_RECRUITING | Local Advanced or Metastatic NSCLC; Harboring EGFR Common Mutation |
Shanghai JMT-Bio Inc. |
2021-11-21 | PHASE2 |
| NCT03940703 | COMPLETED | Non-small Cell Lung Cancer |
EMD Serono Research & Development Institute, Inc. |
2019-09-19 | PHASE2 |
| NCT04959981 | COMPLETED | Advanced Non-squamous Non-small-cell Lung Cancer |
Erasca, Inc. |
2021-09-02 | PHASE1 |
| NCT04035486 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2019-07-02 | PHASE3 |
| NCT04233021 | COMPLETED | Non Small Cell Lung Cancer Metastatic; Leptomeningeal Metastasis; Brain Metastases; EGFR Activating Mutation |
Intergroupe Francophone de Cancerologie Thoracique |
2020-07-16 | PHASE2 |
| NCT05215951 | TERMINATED | Lung Cancer |
AstraZeneca |
2022-01-19 | PHASE2 |
| NCT06303167 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2016-01-08 | PHASE2 |
| NCT03433469 | ACTIVE_NOT_RECRUITING | Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Cancer; Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer |
University of California, San Francisco |
2018-07-31 | PHASE2 |
| NCT03543683 | COMPLETED | Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; EGFR T790M |
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
2018-01-01 | PHASE2 |
| NCT02736513 | UNKNOWN | Lung Cancer |
Soroka University Medical Center |
2016-05 | PHASE2 |
| NCT04816214 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Novartis Pharmaceuticals |
2021-09-22 | PHASE3 |
| NCT04606771 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2020-09-28 | PHASE2 |
| NCT05153408 | TERMINATED | Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR C797S; EGFR C797A; EGFR L858R; EGFR Exon 19 Deletion; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Thoracic Neoplasms; Antineoplastic Agents; Protein Kinase Inhibitors; EGFR C797G; EGFR C797X; Non Small Cell Lung Cancer |
Blueprint Medicines Corporation |
2022-01-13 | PHASE1 |
| NCT04438902 | TERMINATED | Non Small Cell Lung Cancer |
First Affiliated Hospital of Zhejiang University |
2020-12-12 | PHASE2 |
| NCT02824952 | UNKNOWN | Lung Cancer, Non-small Cell |
Shaare Zedek Medical Center |
2018-11-01 | PHASE2 |
| NCT04099836 | TERMINATED | Non Small Cell Lung Cancer |
Duke University |
2020-07-09 | PHASE2 |
| NCT04517526 | UNKNOWN | Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT |
Shanghai Cancer Hospital, China |
2020-11-01 | PHASE2 |
| NCT02520778 | COMPLETED | Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2016-08-30 | PHASE1 |
| NCT03434418 | COMPLETED | Non Small Cell Lung Cancer |
Duke University |
2018-06-30 | PHASE2 |
| NCT03516214 | COMPLETED | Bronchial Neoplasms |
University of Cologne |
2018-04-25 | PHASE1 |
| NCT02856893 | COMPLETED | NSCLC |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-10-10 | PHASE2 |
| NCT05458726 | UNKNOWN | EGFR T790M; Osimertinib; Non-small Cell Lung Cancer; ddPCR |
Peking Union Medical College |
2020-09-15 | PHASE2 |
| NCT02759835 | COMPLETED | Lung Adenocarcinoma; Lung Neoplasms |
National Cancer Institute (NCI) |
2016-04-13 | PHASE2 |
| NCT03891615 | UNKNOWN | Lung Cancer |
Massachusetts General Hospital |
2019-06-06 | PHASE1 |
| NCT04541407 | COMPLETED | Non Small Cell Lung Cancer; CNS Progression |
University of Colorado, Denver |
2020-10-29 | PHASE1 |
| NCT02511106 | ACTIVE_NOT_RECRUITING | Stage IB-IIIA Non-small Cell Lung Carcinoma |
AstraZeneca |
2015-10-21 | PHASE3 |
| NCT03535363 | COMPLETED | NSCLC; Non-small Cell Lung Cancer |
Case Comprehensive Cancer Center |
2018-10-26 | PHASE1 |
| NCT04316351 | UNKNOWN | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy |
Guangzhou Institute of Respiratory Disease |
2020-04-01 | PHASE2 |
| NCT02803203 | COMPLETED | Non-small Cell Lung Cancer; EGFR-mutant Lung Cancers |
Memorial Sloan Kettering Cancer Center |
2016-06-29 | PHASE1; PHASE2 |
| NCT03989115 | COMPLETED | Solid Tumor |
Revolution Medicines, Inc. |
2019-07-02 | PHASE1; PHASE2 |
| NCT03810066 | COMPLETED | NSCLC; EGFR T790M; FDG-PET |
University Hospital, Essen |
2019-06-03 | PHASE2 |
| NCT04448379 | UNKNOWN | Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Shanghai JMT-Bio Inc. |
2020-06-29 | PHASE1 |
| NCT03455829 | COMPLETED | Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-small Cell Lung Cancer |
G1 Therapeutics, Inc. |
2018-03-29 | PHASE1; PHASE2 |
| NCT03858491 | COMPLETED | Non Small Cell Lung Cancer |
Academisch Ziekenhuis Maastricht |
2020-11-01 | EARLY_PHASE1 |
| NCT04798638 | COMPLETED | Healthy Volunteers |
TYK Medicines, Inc |
2021-04-30 | PHASE1 |
| NCT03414814 | COMPLETED | Locally Advanced or Metastatic NSCLC |
Seoul National University Hospital |
2018-01-04 | PHASE2 |
| NCT03381274 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
MedImmune LLC |
2018-05-08 | PHASE1; PHASE2 |
| NCT03784599 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
The Netherlands Cancer Institute |
2018-12-18 | PHASE2 |
| NCT03394118 | COMPLETED | NSCLC |
Asan Medical Center |
2017-08-11 | PHASE2 |
| NCT04148898 | UNKNOWN | Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation |
Second Affiliated Hospital of Nanchang University |
2019-11-01 | PHASE2 |
| NCT03133546 | COMPLETED | Non Small Cell Lung Cancer Metastatic |
ETOP IBCSG Partners Foundation |
2017-05-31 | PHASE2 |
| NCT04338243 | UNKNOWN | Negative T790M Mutation and Met Amplification |
Haihe Biopharma Co., Ltd. |
2019-11-18 | PHASE1; PHASE2 |
| NCT03460275 | UNKNOWN | Non-small Cell Lung Cancer |
Sun Yat-sen University |
2018-02-26 | PHASE2 |
| NCT03255083 | TERMINATED | Non-small Cell Lung Cancer (NSCLC) |
Daiichi Sankyo |
2019-04-10 | PHASE1 |
| NCT04425681 | UNKNOWN | Leptomeningeal Metastasis; Non-small Cell Lung Cancer; EGFR Activating Mutation |
Second Affiliated Hospital of Nanchang University |
2017-10-01 | PHASE2 |
| NCT02771314 | UNKNOWN | Non Small Cell Lung Cancer |
Hellenic Oncology Research Group |
2016-08-02 | PHASE2 |
| NCT03853551 | COMPLETED | Non Small Cell Lung Cancer (NSCLC) |
AstraZeneca |
2019-04-18 | PHASE4 |
| NCT03463525 | COMPLETED | Non-small Cell Lung Cancer |
AstraZeneca |
2018-10-24 | PHASE1 |
| NCT02143466 | ACTIVE_NOT_RECRUITING | Advanced Non Small Cell Lung Cancer |
AstraZeneca |
2014-08-05 | PHASE1 |
| NCT04029350 | UNKNOWN | Non Small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2019-07-31 | PHASE2 |
| NCT03450330 | COMPLETED | Nonsmall Cell Lung Cancer |
Dizal Pharmaceuticals |
2018-04-16 | PHASE1; PHASE2 |
| NCT02972333 | UNKNOWN | EGFR-TKI Resistant Mutation; Nonsmall Cell Lung Cancer; AZD9291; Brain Metastases |
Shandong Cancer Hospital and Institute |
2016-12 | PHASE3 |
| NCT03257124 | UNKNOWN | Non-Small Cell Lung Cancer With EGFR T790M Mutation; With Brain and/or Leptomeningeal Metastasis; Failed Tyrosine Kinase Inhibitors |
Samsung Medical Center |
2017-05-08 | PHASE2 |
| NCT03418532 | TERMINATED | EGFR-mutated NSCLC (Disorder) |
Molecular Partners AG |
2018-03-22 | PHASE1 |
| NCT07271446 | COMPLETED | Non-small Cell Lung Cancer |
Precision Biotech Taiwan Corp. |
2018-09-01 | PHASE1 |
| NCT03050411 | UNKNOWN | Nonsmall Cell Lung Cancer |
Peking University Third Hospital |
2016-05 | PHASE1 |
| NCT02474355 | COMPLETED | Lung Cancer |
AstraZeneca |
2015-09-18 | PHASE3 |
| NCT02811354 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
National University Hospital, Singapore |
2017-02-24 | PHASE2 |
| NCT02411448 | ACTIVE_NOT_RECRUITING | Metastatic Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2015-05-06 | PHASE3 |
| NCT02841579 | COMPLETED | Non-Small Cell Lung Cancer |
MedSIR |
2016-09-02 | PHASE2 |
| NCT02769286 | COMPLETED | Lung Neoplasms; EGFR Gene Mutations |
Chonnam National University Hospital |
2016-08 | PHASE2 |
| NCT02997501 | COMPLETED | Lung Cancer |
AstraZeneca |
2016-12-23 | PHASE3 |
| NCT02923947 | COMPLETED | Solid Tumours |
AstraZeneca |
2017-05-04 | PHASE1 |
| NCT02954523 | TERMINATED | EGFR Gene Mutation; Nonsmall Cell Lung Cancer |
Chul Kim |
2016-10 | PHASE1; PHASE2 |
| NCT03424759 | UNKNOWN | Non Small Cell Lung Cancer |
Samsung Medical Center |
2016-01-01 | PHASE2 |
| NCT02789345 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2016-10-24 | PHASE1 |
| NCT02959749 | COMPLETED | Progression Free Survival |
Qingdao Central Hospital |
2015-08 | PHASE2; PHASE3 |
| NCT02454933 | COMPLETED | Locally Advanced or Metastatic EGFR T790M+ NSCLC |
AstraZeneca |
2015-07-15 | PHASE3 |
| NCT02228369 | COMPLETED | EGFR Mutation Positive Advanced Non Small Cell Lung Cancer |
AstraZeneca |
2014-11-05 | PHASE1 |
| NCT02908750 | COMPLETED | Non Small Cell Lung Cancer |
AstraZeneca |
2017-03-02 | PHASE1 |
| NCT02296125 | COMPLETED | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer |
AstraZeneca |
2014-12-03 | PHASE3 |
| NCT02161770 | COMPLETED | Solid Tumours |
AstraZeneca |
2014-12-22 | PHASE1 |
| NCT02179671 | COMPLETED | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) |
AstraZeneca |
2014-07-25 | PHASE2 |
| NCT02151981 | COMPLETED | Anticancer Treatment |
AstraZeneca |
2014-08-04 | PHASE3 |
| NCT02442349 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2015-06-22 | PHASE2 |
| NCT02529995 | COMPLETED | Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive |
AstraZeneca |
2015-08-24 | PHASE1 |
| NCT02491944 | COMPLETED | Oncology |
AstraZeneca |
2015-07 | PHASE1 |
| NCT02317016 | COMPLETED | Non Small Cell Lung Cancer |
AstraZeneca |
2015-03-10 | PHASE1 |
| NCT02197247 | COMPLETED | Non Small Cell Lung Cancer |
AstraZeneca |
2014-12-04 | PHASE1 |
| NCT02094261 | COMPLETED | Non Small Cell Lung Cancer |
AstraZeneca |
2014-05-20 | PHASE2 |
| NCT01802632 | COMPLETED | Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer |
AstraZeneca |
2013-03-04 | PHASE1; PHASE2 |
| NCT02197234 | COMPLETED | Non Small Cell Lung Cancer |
AstraZeneca |
2014-12-22 | PHASE1 |
| NCT02157883 | COMPLETED | Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer |
AstraZeneca |
2014-11-06 | PHASE1 |
| NCT02163733 | COMPLETED | Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer |
AstraZeneca |
2014-11-14 | PHASE1 |
| NCT02224053 | COMPLETED | Healthy Volunteer |
AstraZeneca |
2014-09 | PHASE1 |
| NCT02096679 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2014-05 | PHASE1 |
| NCT01951599 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2013-10-09 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-03)
Check the
AZD9291 (Osimertinib)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- AZD9291 (Osimertinib) Mechanism of Action: EGFR Inhibition in Non-Small Cell Lung Cancer Cell Research
- AZD9291 (Osimertinib): Selectivity & Specificity
- AZD9291 (Osimertinib) Working Concentration | Cell Culture | Treatment
- AZD9291 (Osimertinib) Solubility in DMSO
- AZD9291 (Osimertinib) Stock Solution
- AZD9291 (Osimertinib) Storage
- AZD9291 (Osimertinib) Stability
- AZD9291 (Osimertinib) Combination Database
- AZD9291 (Osimertinib) Molecular Weight
- AZD9291 (Osimertinib) SMILES
- AZD9291 (Osimertinib) CAS Number
- AZD9291 (Osimertinib) Chemical Structure (2D and 3D)
- AZD9291 (Osimertinib) IC50 for Cell-based and Cell-free Assays
- AZD9291 (Osimertinib) MedChemExpress (HY-15772)? Try a better option.
- AZD9291 (Osimertinib) Cayman (16237)? Try a better option.
- AZD9291 (Osimertinib) Tocris (8873)? Try a better option.
- AZD9291 (Osimertinib) Abmole (M2424)? Try a better option.
- AZD9291 (Osimertinib) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.